November 2012 Editor's Picks: Products from Malvern Instruments and GEA Pharma Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

November 2012 Editor's Picks: Products from Malvern Instruments and GEA Pharma Systems

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Malvern Instruments
Dynamic light scattering system measures microrheology and protein structure


The Zetasizer Nano ZSP is an addition to the Malvern Instruments’ range of dynamic light scattering (DLS) systems. The Nano ZSP measures both size and zeta potential (i.e., electrophoretic mobility) of proteins. A new protein mobility measurement type in the software that controls data acquisition guides the user through the measurement and assesses and reports on data quality. The Nano ZSP uses a new version of Zetasizer software that enables microrheology measurements for the first time on Zetasizer instruments. This DLS-based optical technique allows rheological characterization of weakly-structured and highly strain-sensitive materials using only microliter sample volumes. Applications include measuring the viscosity of polymer and protein solutions and determining the onset of protein aggregation.


GEA Pharma Systems
Continuous high-shear granulation and drying system improves efficiency


The ConsiGma continuous high-shear granulation and drying system from GEA Pharma Systems uses continuous production technology instead of traditional batch technology to produce granules. The system is about one-fourth the size of a traditional granulation line and can run from 500 g for research and development up through production-size batches. Because it is a continuous process, larger amounts do not require a larger machine, but only a longer time. Eliminating scale-up helps reduce development time and cost. ConsiGma has been shown to improve intra-granular porosity and compressibility characteristics.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Equipment and Processing Report,
Click here